Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Triple Negative Breast Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Meningeal Carcinomatosis 1Leukemia, Myeloid, Acute 1Iron Overload 1

Interventions

Pemetrexed 18Bevacizumab 9Spinal Puncture 7Radiotherapy 7Specimen Handling 5Methotrexate 5Magnetic Resonance Spectroscopy 5osimertinib 4aflutinib 4Trastuzumab 3Topotecan 3Temozolomide 3Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2merphos 2lorlatinib 2Vitamin B 12 2Rituximab 2Radiotherapy, Intensity-Modulated 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2tucatinib 1toripalimab 1sintilimab 1sacituzumab govitecan 1pertuzumab 1peginterferon alfa-2b 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Meningeal Carcinomatosis × Deferoxamine × Clear all
NCT05184816 2026-03-27

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
35 enrolled
CNS

Recurrence, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡